Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial

医学 托法替尼 溃疡性结肠炎 安慰剂 优势比 内科学 置信区间 随机化 随机对照试验 人口 英夫利昔单抗 外科 类风湿性关节炎 疾病 替代医学 环境卫生 病理
作者
Arshdeep Singh,Manjeet Kumar Goyal,Vandana Midha,Ramit Mahajan,K. Kaur,YK Gupta,Dharmatma Singh,Namita Bansal,Ramandeep Kaur,Shivam Kalra,Omesh Goyal,Varun Mehta,Ajit Sood
出处
期刊:The American Journal of Gastroenterology [American College of Gastroenterology]
被引量:2
标识
DOI:10.14309/ajg.0000000000002635
摘要

INTRODUCTION: Intravenous corticosteroids are the mainstay of treatment of patients hospitalized with acute severe ulcerative colitis (ASUC). However, 30%–40% of the patients are refractory to corticosteroids. We investigated whether addition of tofacitinib to corticosteroids improved the treatment responsiveness in patients with ASUC. METHODS: This single-center, double-blind, placebo-controlled trial randomized adult patients with ASUC (defined by the Truelove Witts severity criteria) to receive either tofacitinib (10 mg thrice daily) or a matching placebo for 7 days while continuing intravenous corticosteroids (hydrocortisone 100 mg every 6 hours). The primary end point was response to treatment (decline in the Lichtiger index by >3 points and an absolute score <10 for 2 consecutive days without the need for rescue therapy) by day 7. The key secondary outcome was the cumulative probability of requiring initiation of infliximab or undergoing colectomy within 90 days following randomization. All analyses were performed in the intention-to-treat population. RESULTS: A total of 104 patients were randomly assigned to a treatment group (53 to tofacitinib and 51 to placebo). At day 7, response to treatment was achieved in 44/53 (83.01%) patients receiving tofacitinib vs 30/51 (58.82%) patients receiving placebo (odds ratio 3.42, 95% confidence interval 1.37–8.48, P = 0.007). The need for rescue therapy by day 7 was lower in the tofacitinib arm (odds ratio 0.27, 95% confidence interval 0.09–0.78, P = 0.01). The cumulative probability of need for rescue therapy at day 90 was 0.13 in patients who received tofacitinib vs 0.38 in patients receiving placebo (log-rank P = 0.003). Most of the treatment-related adverse effects were mild. One patient, receiving tofacitinib, developed dural venous sinus thrombosis. DISCUSSION: In patients with ASUC, combination of tofacitinib and corticosteroids improved treatment responsiveness and decreased the need for rescue therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
华仔应助研友_pLwBm8采纳,获得10
刚刚
刚刚
JQB发布了新的文献求助10
刚刚
王振123654完成签到,获得积分10
3秒前
田様应助超级日记本采纳,获得10
4秒前
owldan发布了新的文献求助10
7秒前
7秒前
power完成签到,获得积分10
12秒前
沐风完成签到 ,获得积分10
14秒前
14秒前
FashionBoy应助lxrsee采纳,获得10
16秒前
互助遵法尚德应助岑寂采纳,获得10
17秒前
小蚊子发布了新的文献求助10
18秒前
棠梨浮萍完成签到,获得积分10
19秒前
21秒前
21秒前
蕊蕊发布了新的文献求助10
23秒前
Hello应助随遇而安采纳,获得10
25秒前
25秒前
天真如松发布了新的文献求助10
25秒前
解洙发布了新的文献求助10
26秒前
共享精神应助淡然傻姑采纳,获得10
26秒前
lxy完成签到,获得积分10
28秒前
田様应助花芷采纳,获得10
29秒前
活泼的烙完成签到,获得积分10
29秒前
31秒前
小二郎应助研友_8KA32n采纳,获得10
33秒前
33秒前
随遇而安发布了新的文献求助10
35秒前
36秒前
tyjj发布了新的文献求助10
37秒前
39秒前
41秒前
cctv18应助gscholer采纳,获得10
42秒前
星辰大海应助蕊蕊采纳,获得10
42秒前
花芷发布了新的文献求助10
42秒前
科目三应助长欢采纳,获得10
46秒前
研友_8KA32n发布了新的文献求助10
47秒前
yml发布了新的文献求助20
51秒前
研友_8KA32n完成签到,获得积分10
53秒前
高分求助中
The three stars each : the Astrolabes and related texts 1070
Manual of Clinical Microbiology, 4 Volume Set (ASM Books) 13th Edition 1000
Hieronymi Mercurialis Foroliviensis De arte gymnastica libri sex: In quibus exercitationum omnium vetustarum genera, loca, modi, facultates, & ... exercitationes pertinet diligenter explicatur Hardcover – 26 August 2016 900
Sport in der Antike 800
De arte gymnastica. The art of gymnastics 600
少脉山油柑叶的化学成分研究 530
Sport in der Antike Hardcover – March 1, 2015 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2404593
求助须知:如何正确求助?哪些是违规求助? 2103160
关于积分的说明 5307788
捐赠科研通 1830694
什么是DOI,文献DOI怎么找? 912201
版权声明 560502
科研通“疑难数据库(出版商)”最低求助积分说明 487712